Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.